# Tilray Medical Enters Panama Market with CBD Oral Solution from Portugal Facility > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/tilray-medical-enters-panama-market-with-cbd-oral-solution-from-portugal-facility/ > **Published:** 2026-07-12T17:16:31-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:19:50-04:00 > **Clinical Summary:** Tilray's pharmaceutical-grade CBD oral solution enters Panama. Learn what standardized cannabis medicine means for patient safety and access. --- ✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. CBDIndustrySafetyPolicyHempPainAnxiety Why This Matters This market expansion increases geographic access to regulated, quality-controlled [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) for patients in Panama and Central America who may lack consistent pharmaceutical-grade options. Clinicians treating patients in these regions can now reference standardized dosing and safety data from an established producer rather than advising patients toward unregulated alternatives. The availability of pharmaceutical-grade CBD with consistent quality strengthens the clinical evidence base for CBD therapy by reducing variability in patient outcomes across different geographic markets. Clinical Summary Tilray Medical has expanded its pharmaceutical-grade cannabis operations into Panama by introducing a CBD oral solution manufactured at its Portuguese facility, representing a strategic effort to increase access to standardized [medical cannabis products](https://cedclinic.com/cannabis-infused-products-skin-diy-topical-recipes/) in Central American markets. This expansion reflects the broader industry trend toward establishing regulated supply chains and GMP-compliant production facilities that can serve multiple jurisdictions, addressing the clinical need for consistent, quality-controlled cannabis formulations. For clinicians in regions gaining access to these products, pharmaceutical-grade CBD from established manufacturers offers greater assurance regarding product purity, potency accuracy, and absence of contaminants compared to unregulated sources. The availability of such products in Panama may influence prescribing patterns in that region and neighboring countries where regulatory frameworks are evolving to accommodate medical cannabis. Clinicians should remain informed about which cannabis products available to their patients meet pharmaceutical standards, as this directly impacts the reliability of dosing and safety profiles when recommending or discussing [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) with patients. Dr. Caplan’s Take “While access to pharmaceutical-grade cannabis products in new markets is valuable from a patient care perspective, I’d note that this is primarily a business and regulatory development rather than new clinical evidence. What matters most for my patients in Panama is whether these products have undergone rigorous efficacy and safety testing in peer-reviewed trials for their specific indications, not simply that they meet manufacturing standards.” Clinical Perspective 💊 Tilray’s expansion of pharmaceutical-grade [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) into Panama reflects the growing international momentum toward regulated [medical cannabis access](https://cedclinic.com/medical-marijuana-card-reciprocity/) in regions with limited prior infrastructure. While such market entry promises standardized formulations and quality assurance that differ markedly from unregulated products, clinicians should recognize that regulatory frameworks vary substantially across jurisdictions, and the evidence base for specific CBD oral solutions remains limited to particular indications and patient populations. The availability of “pharmaceutical-grade” products does not automatically establish clinical superiority over other preparations for all conditions, and providers must still appraise individual patient data and local evidence rather than assume that market expansion signals definitive therapeutic benefit. In practice, as cannabis-based medicines become more accessible globally, clinicians in regions gaining regulated access should prioritize gathering baseline and follow-up clinical data on efficacy and safety, consulting available evidence syntheses for their specific indication, and remaining cautious about patient expectations shaped by direct-to-consumer marketing rather 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Tilray%20Medical%20Enters%20Panama%20Market%20with%20CBD%20Oral%20Solution%20from%20Portugal%20Facility%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D69235)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D69235)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Tilray%20Medical%20Enters%20Panama%20Market%20with%20CBD%20Oral%20Solution%20from%20Portugal%20Facility%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D69235)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://stratcann.com/news/tilray-medical-enters-panama-market-with-cbd-oral-solution-from-portugal-facility/](https://stratcann.com/news/tilray-medical-enters-panama-market-with-cbd-oral-solution-from-portugal-facility/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).